

Pharmacovigilance Market By Type (Services, Software), By Process Flow (Pre-marketing, Post-marketing), By Deployment (In House, Contract Outsourcing), By Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, Others): Global Opportunity Analysis and Industry Forecast, 2025-2034

<https://marketpublishers.com/r/P9502064F9AAEN.html>

Date: August 2025

Pages: 391

Price: US\$ 2,655.00 (Single User License)

ID: P9502064F9AAEN

Abstracts

The pharmacovigilance market was valued at \$8,202.49 million in 2024 and is estimated to reach \$26,212.81 million by 2034, exhibiting a CAGR of 12.3% from 2025 to 2034.

The process of detection, understanding, assessment and prevention of adverse effects associated with drugs is termed as pharmacovigilance. It is important for ensuring the efficacy and safety of pharmaceutical products. It is majorly used in healthcare and pharmaceutical sectors across the globe.

Rise in incidences of adverse drug reactions, rise in cases of drug toxicity, and surge in complexity of drug development makes way for the increase in demand for pharmacovigilance. In addition, rise in biologics and personalized medicines also boosts the growth of the pharmacovigilance market. Moreover, rise in drug developments for rare diseases increases the need for drug safety assessments, which fosters the pharmacovigilance market growth. However, rise in associated costs and surge in complexity of pharmacovigilance activities limits the market growth. The small and mid-sized sectors are budget-conscious and hence replan the investment in pharmacovigilance services. Also, shortage of skilled professionals in pharmacovigilance sector is another factor limiting the growth of the market.

Nevertheless, outsourcing pharmacovigilance services to contract research organizations and surge in advancements in technology, which includes usage of artificial intelligence, cloud-based platforms, and automation in pharmacovigilance sector is projected to boost the growth of the pharmacovigilance market during the forecast period.

The pharmacovigilance market is segmented into type, process flow, deployment, therapeutic area, and region. On the basis of type, it is bifurcated into services and software. The service segment is further divided into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, and others**. On the basis of process flow, the market is segregated into pre-marketing and post-marketing. On the basis of deployment, the market is categorized into in-house and contract outsourcing. On the basis of therapeutic area, the market is classified into oncology, neurology**, cardiology, respiratory system and others. Region-wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Accenture**, Cognizant, Oracle Corporation, Labcorp, ICON Plc., Capgemini, Clario, Wipro Limited, IQVIA, and Parexel. The key players operating in the market have adopted collaboration, and partnership as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of pharmacovigilance market analysis from 2024 to 2034 to identify the prevailing pharmacovigilance market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the pharmacovigilance market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to

the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global pharmacovigilance market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)

5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

Free Upcoming Version on the Purchase of Five and Enterprise User License.

16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

Free data Pack on the Five and Enterprise User License. (Excel version of the report)

Free Updated report if the report is 6-12 months old or older.

24-hour priority response*

Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Additional company profiles with specific to client's interest

Expanded list for Company Profiles

Historic market data

Key Market Segments By Type

Services

Type

Spontaneous Reporting

Intensified ADR Reporting

Targeted Spontaneous Reporting

Others

Software

By Process Flow

Pre-marketing

Post-marketing

By Deployment

In House

Contract Outsourcing

By Therapeutic Area

Neurology

Cardiology

Respiratory Systems

Others

Oncology

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

Key Market Players

Cognizant

Oracle Corporation

labcorp

ICON Plc

Capgemini

Wipro Limited

IQVIA

Parexel

Clario

Accenture

Contents

CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
 - 1.4.1. Primary research
 - 1.4.2. Secondary research
 - 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
 - 3.2.1. Top impacting factors
 - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
 - 3.3.1. Moderate bargaining power of suppliers
 - 3.3.2. High threat of new entrants
 - 3.3.3. Moderate threat of substitutes
 - 3.3.4. Moderate intensity of rivalry
 - 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
 - 3.4.1. Drivers
 - 3.4.1.1. Rising Volume of Adverse Drug Reactions (ADRs) and Regulatory Pressure
 - 3.4.1.2. Growth in Clinical Trials and New Drug Approvals
 - 3.4.1.3. Integration of AI and Automation in Drug Safety Monitoring
 - 3.4.2. Restraints
 - 3.4.2.1. High Cost and Complexity of Implementation
 - 3.4.3. Opportunities
 - 3.4.3.1. Expansion in Emerging Markets and Pharmacovigilance Outsourcing

CHAPTER 4: PHARMACOVIGILANCE MARKET, BY TYPE

Pharmacovigilance Market By Type (Services, Software), By Process Flow (Pre-marketing, Post-marketing), By Dep...

4.1. Overview

4.1.1. Market size and forecast

4.2. Services

4.2.1. Key market trends, growth factors and opportunities

4.2.2. Market size and forecast, by region

4.2.3. Market share analysis by country

4.2.4. Services Pharmacovigilance Market by Type

4.2.4.1. Spontaneous Reporting Market size and forecast, by region

4.2.4.2. Spontaneous Reporting Market size and forecast, by country

4.2.4.3. Intensified ADR Reporting Market size and forecast, by region

4.2.4.4. Intensified ADR Reporting Market size and forecast, by country

4.2.4.5. Targeted Spontaneous Reporting Market size and forecast, by region

4.2.4.6. Targeted Spontaneous Reporting Market size and forecast, by country

4.2.4.7. Others Market size and forecast, by region

4.2.4.8. Others Market size and forecast, by country

4.3. Software

4.3.1. Key market trends, growth factors and opportunities

4.3.2. Market size and forecast, by region

4.3.3. Market share analysis by country

CHAPTER 5: PHARMACOVIGILANCE MARKET, BY PROCESS FLOW

5.1. Overview

5.1.1. Market size and forecast

5.2. Pre-marketing

5.2.1. Key market trends, growth factors and opportunities

5.2.2. Market size and forecast, by region

5.2.3. Market share analysis by country

5.3. Post-marketing

5.3.1. Key market trends, growth factors and opportunities

5.3.2. Market size and forecast, by region

5.3.3. Market share analysis by country

CHAPTER 6: PHARMACOVIGILANCE MARKET, BY DEPLOYMENT

6.1. Overview

6.1.1. Market size and forecast

6.2. In House

- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Contract Outsourcing
 - 6.3.1. Key market trends, growth factors and opportunities
 - 6.3.2. Market size and forecast, by region
 - 6.3.3. Market share analysis by country

CHAPTER 7: PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA

- 7.1. Overview
 - 7.1.1. Market size and forecast
- 7.2. Oncology
 - 7.2.1. Key market trends, growth factors and opportunities
 - 7.2.2. Market size and forecast, by region
 - 7.2.3. Market share analysis by country
- 7.3. Neurology
 - 7.3.1. Key market trends, growth factors and opportunities
 - 7.3.2. Market size and forecast, by region
 - 7.3.3. Market share analysis by country
- 7.4. Cardiology
 - 7.4.1. Key market trends, growth factors and opportunities
 - 7.4.2. Market size and forecast, by region
 - 7.4.3. Market share analysis by country
- 7.5. Respiratory Systems
 - 7.5.1. Key market trends, growth factors and opportunities
 - 7.5.2. Market size and forecast, by region
 - 7.5.3. Market share analysis by country
- 7.6. Others
 - 7.6.1. Key market trends, growth factors and opportunities
 - 7.6.2. Market size and forecast, by region
 - 7.6.3. Market share analysis by country

CHAPTER 8: PHARMACOVIGILANCE MARKET, BY REGION

- 8.1. Overview
 - 8.1.1. Market size and forecast By Region
- 8.2. North America
 - 8.2.1. Key market trends, growth factors and opportunities

8.2.2. Market size and forecast, by Type

8.2.2.1. North America Services Pharmacovigilance Market by Type

8.2.3. Market size and forecast, by Process Flow

8.2.4. Market size and forecast, by Deployment

8.2.5. Market size and forecast, by Therapeutic Area

8.2.6. Market size and forecast, by country

8.2.6.1. U.S.

8.2.6.1.1. Market size and forecast, by Type

8.2.6.1.1.1. U.S. Services Pharmacovigilance Market by Type

8.2.6.1.2. Market size and forecast, by Process Flow

8.2.6.1.3. Market size and forecast, by Deployment

8.2.6.1.4. Market size and forecast, by Therapeutic Area

8.2.6.2. Canada

8.2.6.2.1. Market size and forecast, by Type

8.2.6.2.1.1. Canada Services Pharmacovigilance Market by Type

8.2.6.2.2. Market size and forecast, by Process Flow

8.2.6.2.3. Market size and forecast, by Deployment

8.2.6.2.4. Market size and forecast, by Therapeutic Area

8.2.6.3. Mexico

8.2.6.3.1. Market size and forecast, by Type

8.2.6.3.1.1. Mexico Services Pharmacovigilance Market by Type

8.2.6.3.2. Market size and forecast, by Process Flow

8.2.6.3.3. Market size and forecast, by Deployment

8.2.6.3.4. Market size and forecast, by Therapeutic Area

8.3. Europe

8.3.1. Key market trends, growth factors and opportunities

8.3.2. Market size and forecast, by Type

8.3.2.1. Europe Services Pharmacovigilance Market by Type

8.3.3. Market size and forecast, by Process Flow

8.3.4. Market size and forecast, by Deployment

8.3.5. Market size and forecast, by Therapeutic Area

8.3.6. Market size and forecast, by country

8.3.6.1. Germany

8.3.6.1.1. Market size and forecast, by Type

8.3.6.1.1.1. Germany Services Pharmacovigilance Market by Type

8.3.6.1.2. Market size and forecast, by Process Flow

8.3.6.1.3. Market size and forecast, by Deployment

8.3.6.1.4. Market size and forecast, by Therapeutic Area

8.3.6.2. France

8.3.6.2.1. Market size and forecast, by Type

8.3.6.2.1.1. France Services Pharmacovigilance Market by Type

8.3.6.2.2. Market size and forecast, by Process Flow

8.3.6.2.3. Market size and forecast, by Deployment

8.3.6.2.4. Market size and forecast, by Therapeutic Area

8.3.6.3. UK

8.3.6.3.1. Market size and forecast, by Type

8.3.6.3.1.1. UK Services Pharmacovigilance Market by Type

8.3.6.3.2. Market size and forecast, by Process Flow

8.3.6.3.3. Market size and forecast, by Deployment

8.3.6.3.4. Market size and forecast, by Therapeutic Area

8.3.6.4. Italy

8.3.6.4.1. Market size and forecast, by Type

8.3.6.4.1.1. Italy Services Pharmacovigilance Market by Type

8.3.6.4.2. Market size and forecast, by Process Flow

8.3.6.4.3. Market size and forecast, by Deployment

8.3.6.4.4. Market size and forecast, by Therapeutic Area

8.3.6.5. Spain

8.3.6.5.1. Market size and forecast, by Type

8.3.6.5.1.1. Spain Services Pharmacovigilance Market by Type

8.3.6.5.2. Market size and forecast, by Process Flow

8.3.6.5.3. Market size and forecast, by Deployment

8.3.6.5.4. Market size and forecast, by Therapeutic Area

8.3.6.6. Rest of Europe

8.3.6.6.1. Market size and forecast, by Type

8.3.6.6.1.1. Rest of Europe Services Pharmacovigilance Market by Type

8.3.6.6.2. Market size and forecast, by Process Flow

8.3.6.6.3. Market size and forecast, by Deployment

8.3.6.6.4. Market size and forecast, by Therapeutic Area

8.4. Asia-Pacific

8.4.1. Key market trends, growth factors and opportunities

8.4.2. Market size and forecast, by Type

8.4.2.1. Asia-Pacific Services Pharmacovigilance Market by Type

8.4.3. Market size and forecast, by Process Flow

8.4.4. Market size and forecast, by Deployment

8.4.5. Market size and forecast, by Therapeutic Area

8.4.6. Market size and forecast, by country

8.4.6.1. Japan

8.4.6.1.1. Market size and forecast, by Type

- 8.4.6.1.1.1. Japan Services Pharmacovigilance Market by Type
- 8.4.6.1.2. Market size and forecast, by Process Flow
- 8.4.6.1.3. Market size and forecast, by Deployment
- 8.4.6.1.4. Market size and forecast, by Therapeutic Area
- 8.4.6.2. China
 - 8.4.6.2.1. Market size and forecast, by Type
 - 8.4.6.2.1.1. China Services Pharmacovigilance Market by Type
 - 8.4.6.2.2. Market size and forecast, by Process Flow
 - 8.4.6.2.3. Market size and forecast, by Deployment
 - 8.4.6.2.4. Market size and forecast, by Therapeutic Area
- 8.4.6.3. India
 - 8.4.6.3.1. Market size and forecast, by Type
 - 8.4.6.3.1.1. India Services Pharmacovigilance Market by Type
 - 8.4.6.3.2. Market size and forecast, by Process Flow
 - 8.4.6.3.3. Market size and forecast, by Deployment
 - 8.4.6.3.4. Market size and forecast, by Therapeutic Area
- 8.4.6.4. Australia
 - 8.4.6.4.1. Market size and forecast, by Type
 - 8.4.6.4.1.1. Australia Services Pharmacovigilance Market by Type
 - 8.4.6.4.2. Market size and forecast, by Process Flow
 - 8.4.6.4.3. Market size and forecast, by Deployment
 - 8.4.6.4.4. Market size and forecast, by Therapeutic Area
- 8.4.6.5. South Korea
 - 8.4.6.5.1. Market size and forecast, by Type
 - 8.4.6.5.1.1. South Korea Services Pharmacovigilance Market by Type
 - 8.4.6.5.2. Market size and forecast, by Process Flow
 - 8.4.6.5.3. Market size and forecast, by Deployment
 - 8.4.6.5.4. Market size and forecast, by Therapeutic Area
- 8.4.6.6. Rest of Asia-Pacific
 - 8.4.6.6.1. Market size and forecast, by Type
 - 8.4.6.6.1.1. Rest of Asia-Pacific Services Pharmacovigilance Market by Type
 - 8.4.6.6.2. Market size and forecast, by Process Flow
 - 8.4.6.6.3. Market size and forecast, by Deployment
 - 8.4.6.6.4. Market size and forecast, by Therapeutic Area
- 8.5. LAMEA
 - 8.5.1. Key market trends, growth factors and opportunities
 - 8.5.2. Market size and forecast, by Type
 - 8.5.2.1. LAMEA Services Pharmacovigilance Market by Type
 - 8.5.3. Market size and forecast, by Process Flow

- 8.5.4. Market size and forecast, by Deployment
- 8.5.5. Market size and forecast, by Therapeutic Area
- 8.5.6. Market size and forecast, by country
 - 8.5.6.1. Brazil
 - 8.5.6.1.1. Market size and forecast, by Type
 - 8.5.6.1.1.1. Brazil Services Pharmacovigilance Market by Type
 - 8.5.6.1.2. Market size and forecast, by Process Flow
 - 8.5.6.1.3. Market size and forecast, by Deployment
 - 8.5.6.1.4. Market size and forecast, by Therapeutic Area
 - 8.5.6.2. Saudi Arabia
 - 8.5.6.2.1. Market size and forecast, by Type
 - 8.5.6.2.1.1. Saudi Arabia Services Pharmacovigilance Market by Type
 - 8.5.6.2.2. Market size and forecast, by Process Flow
 - 8.5.6.2.3. Market size and forecast, by Deployment
 - 8.5.6.2.4. Market size and forecast, by Therapeutic Area
 - 8.5.6.3. South Africa
 - 8.5.6.3.1. Market size and forecast, by Type
 - 8.5.6.3.1.1. South Africa Services Pharmacovigilance Market by Type
 - 8.5.6.3.2. Market size and forecast, by Process Flow
 - 8.5.6.3.3. Market size and forecast, by Deployment
 - 8.5.6.3.4. Market size and forecast, by Therapeutic Area
 - 8.5.6.4. Rest of LAMEA
 - 8.5.6.4.1. Market size and forecast, by Type
 - 8.5.6.4.1.1. Rest of LAMEA Services Pharmacovigilance Market by Type
 - 8.5.6.4.2. Market size and forecast, by Process Flow
 - 8.5.6.4.3. Market size and forecast, by Deployment
 - 8.5.6.4.4. Market size and forecast, by Therapeutic Area

CHAPTER 9: COMPETITIVE LANDSCAPE

- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product mapping of top 10 player
- 9.4. Competitive dashboard
- 9.5. Competitive heatmap
- 9.6. Top player positioning, 2024

CHAPTER 10: COMPANY PROFILES

- 10.1. Accenture
 - 10.1.1. Company overview
 - 10.1.2. Key executives
 - 10.1.3. Company snapshot
 - 10.1.4. Operating business segments
 - 10.1.5. Product portfolio
 - 10.1.6. Business performance
- 10.2. Cognizant
 - 10.2.1. Company overview
 - 10.2.2. Key executives
 - 10.2.3. Company snapshot
 - 10.2.4. Operating business segments
 - 10.2.5. Product portfolio
 - 10.2.6. Business performance
 - 10.2.7. Key strategic moves and developments
- 10.3. Oracle Corporation
 - 10.3.1. Company overview
 - 10.3.2. Key executives
 - 10.3.3. Company snapshot
 - 10.3.4. Operating business segments
 - 10.3.5. Product portfolio
 - 10.3.6. Business performance
- 10.4. labcorp
 - 10.4.1. Company overview
 - 10.4.2. Key executives
 - 10.4.3. Company snapshot
 - 10.4.4. Operating business segments
 - 10.4.5. Product portfolio
 - 10.4.6. Business performance
- 10.5. Wipro Limited
 - 10.5.1. Company overview
 - 10.5.2. Key executives
 - 10.5.3. Company snapshot
 - 10.5.4. Operating business segments
 - 10.5.5. Product portfolio
 - 10.5.6. Business performance
- 10.6. ICON Plc
 - 10.6.1. Company overview
 - 10.6.2. Key executives

- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
- 10.6.7. Key strategic moves and developments
- 10.7. Capgemini
 - 10.7.1. Company overview
 - 10.7.2. Key executives
 - 10.7.3. Company snapshot
 - 10.7.4. Operating business segments
 - 10.7.5. Product portfolio
 - 10.7.6. Business performance
- 10.8. Clario
 - 10.8.1. Company overview
 - 10.8.2. Key executives
 - 10.8.3. Company snapshot
 - 10.8.4. Operating business segments
 - 10.8.5. Product portfolio
- 10.9. IQVIA
 - 10.9.1. Company overview
 - 10.9.2. Key executives
 - 10.9.3. Company snapshot
 - 10.9.4. Operating business segments
 - 10.9.5. Product portfolio
 - 10.9.6. Business performance
 - 10.9.7. Key strategic moves and developments
- 10.10. Parexel
 - 10.10.1. Company overview
 - 10.10.2. Key executives
 - 10.10.3. Company snapshot
 - 10.10.4. Operating business segments
 - 10.10.5. Product portfolio
 - 10.10.6. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 01. GLOBAL PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 02. PHARMACOVIGILANCE MARKET FOR SERVICES, BY REGION, 2024-2034 (\$MILLION)

TABLE 03. GLOBAL SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 04. PHARMACOVIGILANCE MARKET FOR SPONTANEOUS REPORTING, BY REGION, 2024-2034 (\$MILLION)

TABLE 05. PHARMACOVIGILANCE MARKET FOR INTENSIFIED ADR REPORTING, BY REGION, 2024-2034 (\$MILLION)

TABLE 06. PHARMACOVIGILANCE MARKET FOR TARGETED SPONTANEOUS REPORTING, BY REGION, 2024-2034 (\$MILLION)

TABLE 07. PHARMACOVIGILANCE MARKET FOR OTHERS, BY REGION, 2024-2034 (\$MILLION)

TABLE 08. PHARMACOVIGILANCE MARKET FOR SOFTWARE, BY REGION, 2024-2034 (\$MILLION)

TABLE 09. GLOBAL PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 10. PHARMACOVIGILANCE MARKET FOR PRE-MARKETING, BY REGION, 2024-2034 (\$MILLION)

TABLE 11. PHARMACOVIGILANCE MARKET FOR POST-MARKETING, BY REGION, 2024-2034 (\$MILLION)

TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 13. PHARMACOVIGILANCE MARKET FOR IN HOUSE, BY REGION, 2024-2034 (\$MILLION)

TABLE 14. PHARMACOVIGILANCE MARKET FOR CONTRACT OUTSOURCING, BY REGION, 2024-2034 (\$MILLION)

TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 16. PHARMACOVIGILANCE MARKET FOR ONCOLOGY, BY REGION, 2024-2034 (\$MILLION)

TABLE 17. PHARMACOVIGILANCE MARKET FOR NEUROLOGY, BY REGION, 2024-2034 (\$MILLION)

TABLE 18. PHARMACOVIGILANCE MARKET FOR CARDIOLOGY, BY REGION,

2024-2034 (\$MILLION)

TABLE 19. PHARMACOVIGILANCE MARKET FOR RESPIRATORY SYSTEMS, BY REGION, 2024-2034 (\$MILLION)

TABLE 20. PHARMACOVIGILANCE MARKET FOR OTHERS, BY REGION, 2024-2034 (\$MILLION)

TABLE 21. PHARMACOVIGILANCE MARKET, BY REGION, 2024-2034 (\$MILLION)

TABLE 22. NORTH AMERICA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 23. NORTH AMERICA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 24. NORTH AMERICA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 25. NORTH AMERICA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 26. NORTH AMERICA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 27. NORTH AMERICA PHARMACOVIGILANCE MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 28. U.S. PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 29. U.S. SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 30. U.S. PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 31. U.S. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 32. U.S. PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 33. CANADA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 34. CANADA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 35. CANADA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 36. CANADA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 37. CANADA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 38. MEXICO PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 39. MEXICO SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 40. MEXICO PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 41. MEXICO PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 42. MEXICO PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 43. EUROPE PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 44. EUROPE SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 45. EUROPE PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 46. EUROPE PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 47. EUROPE PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 48. EUROPE PHARMACOVIGILANCE MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 49. GERMANY PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 50. GERMANY SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 51. GERMANY PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 52. GERMANY PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 53. GERMANY PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 54. FRANCE PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 55. FRANCE SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 56. FRANCE PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 57. FRANCE PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 58. FRANCE PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA,

2024-2034 (\$MILLION)

TABLE 59. UK PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 60. UK SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 61. UK PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 62. UK PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 63. UK PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 64. ITALY PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 65. ITALY SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 66. ITALY PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 67. ITALY PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 68. ITALY PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 69. SPAIN PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 70. SPAIN SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 71. SPAIN PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 72. SPAIN PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 73. SPAIN PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 74. REST OF EUROPE PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 75. REST OF EUROPE SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 76. REST OF EUROPE PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 77. REST OF EUROPE PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 78. REST OF EUROPE PHARMACOVIGILANCE MARKET, BY

THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 79. ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 80. ASIA-PACIFIC SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 81. ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 82. ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 83. ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 84. ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY COUNTRY, 2024-2034 (\$MILLION)

TABLE 85. JAPAN PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 86. JAPAN SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 87. JAPAN PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 88. JAPAN PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 89. JAPAN PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 90. CHINA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 91. CHINA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 92. CHINA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 93. CHINA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 94. CHINA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 95. INDIA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 96. INDIA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 97. INDIA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 98. INDIA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 99. INDIA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 100. AUSTRALIA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 101. AUSTRALIA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 102. AUSTRALIA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 103. AUSTRALIA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 104. AUSTRALIA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 105. SOUTH KOREA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 106. SOUTH KOREA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 107. SOUTH KOREA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 108. SOUTH KOREA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 109. SOUTH KOREA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 110. REST OF ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 111. REST OF ASIA-PACIFIC SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 112. REST OF ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 113. REST OF ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 114. REST OF ASIA-PACIFIC PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 115. LAMEA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 116. LAMEA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 117. LAMEA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW,

2024-2034 (\$MILLION)

TABLE 118. LAMEA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT,
2024-2034 (\$MILLION)

TABLE 119. LAMEA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA,
2024-2034 (\$MILLION)

TABLE 120. LAMEA PHARMACOVIGILANCE MARKET, BY COUNTRY, 2024-2034
(\$MILLION)

TABLE 121. BRAZIL PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034
(\$MILLION)

TABLE 122. BRAZIL SERVICES PHARMACOVIGILANCE MARKET, BY TYPE,
2024-2034 (\$MILLION)

TABLE 123. BRAZIL PHARMACOVIGILANCE MARKET, BY PROCESS FLOW,
2024-2034 (\$MILLION)

TABLE 124. BRAZIL PHARMACOVIGILANCE MARKET, BY DEPLOYMENT,
2024-2034 (\$MILLION)

TABLE 125. BRAZIL PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA,
2024-2034 (\$MILLION)

TABLE 126. SAUDI ARABIA PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034
(\$MILLION)

TABLE 127. SAUDI ARABIA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE,
2024-2034 (\$MILLION)

TABLE 128. SAUDI ARABIA PHARMACOVIGILANCE MARKET, BY PROCESS
FLOW, 2024-2034 (\$MILLION)

TABLE 129. SAUDI ARABIA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT,
2024-2034 (\$MILLION)

TABLE 130. SAUDI ARABIA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC
AREA, 2024-2034 (\$MILLION)

TABLE 131. SOUTH AFRICA PHARMACOVIGILANCE MARKET, BY TYPE,
2024-2034 (\$MILLION)

TABLE 132. SOUTH AFRICA SERVICES PHARMACOVIGILANCE MARKET, BY
TYPE, 2024-2034 (\$MILLION)

TABLE 133. SOUTH AFRICA PHARMACOVIGILANCE MARKET, BY PROCESS
FLOW, 2024-2034 (\$MILLION)

TABLE 134. SOUTH AFRICA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT,
2024-2034 (\$MILLION)

TABLE 135. SOUTH AFRICA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC
AREA, 2024-2034 (\$MILLION)

TABLE 136. REST OF LAMEA PHARMACOVIGILANCE MARKET, BY TYPE,
2024-2034 (\$MILLION)

TABLE 137. REST OF LAMEA SERVICES PHARMACOVIGILANCE MARKET, BY TYPE, 2024-2034 (\$MILLION)

TABLE 138. REST OF LAMEA PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024-2034 (\$MILLION)

TABLE 139. REST OF LAMEA PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024-2034 (\$MILLION)

TABLE 140. REST OF LAMEA PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024-2034 (\$MILLION)

TABLE 141. ACCENTURE: KEY EXECUTIVES

TABLE 142. ACCENTURE: COMPANY SNAPSHOT

TABLE 143. ACCENTURE: SERVICE SEGMENTS

TABLE 144. ACCENTURE: PRODUCT PORTFOLIO

TABLE 145. COGNIZANT: KEY EXECUTIVES

TABLE 146. COGNIZANT: COMPANY SNAPSHOT

TABLE 147. COGNIZANT: SERVICE SEGMENTS

TABLE 148. COGNIZANT: PRODUCT PORTFOLIO

TABLE 149. COGNIZANT: KEY STRATEGIES

TABLE 150. ORACLE CORPORATION: KEY EXECUTIVES

TABLE 151. ORACLE CORPORATION: COMPANY SNAPSHOT

TABLE 152. ORACLE CORPORATION: SERVICE SEGMENTS

TABLE 153. ORACLE CORPORATION: PRODUCT PORTFOLIO

TABLE 154. LABCORP: KEY EXECUTIVES

TABLE 155. LABCORP: COMPANY SNAPSHOT

TABLE 156. LABCORP: SERVICE SEGMENTS

TABLE 157. LABCORP: PRODUCT PORTFOLIO

TABLE 158. WIPRO LIMITED: KEY EXECUTIVES

TABLE 159. WIPRO LIMITED: COMPANY SNAPSHOT

TABLE 160. WIPRO LIMITED: PRODUCT SEGMENTS

TABLE 161. WIPRO LIMITED: SERVICE SEGMENTS

TABLE 162. WIPRO LIMITED: PRODUCT PORTFOLIO

TABLE 163. ICON PLC: KEY EXECUTIVES

TABLE 164. ICON PLC: COMPANY SNAPSHOT

TABLE 165. ICON PLC: SERVICE SEGMENTS

TABLE 166. ICON PLC: PRODUCT PORTFOLIO

TABLE 167. ICON PLC: KEY STRATEGIES

TABLE 168. CAPGEMINI: KEY EXECUTIVES

TABLE 169. CAPGEMINI: COMPANY SNAPSHOT

TABLE 170. CAPGEMINI: SERVICE SEGMENTS

TABLE 171. CAPGEMINI: PRODUCT PORTFOLIO

TABLE 172. CLARIO: KEY EXECUTIVES
TABLE 173. CLARIO: COMPANY SNAPSHOT
TABLE 174. CLARIO: PRODUCT SEGMENTS
TABLE 175. CLARIO: PRODUCT PORTFOLIO
TABLE 176. IQVIA: KEY EXECUTIVES
TABLE 177. IQVIA: COMPANY SNAPSHOT
TABLE 178. IQVIA: PRODUCT SEGMENTS
TABLE 179. IQVIA: PRODUCT PORTFOLIO
TABLE 180. IQVIA: KEY STRATERGIES
TABLE 181. PAREXEL: KEY EXECUTIVES
TABLE 182. PAREXEL: COMPANY SNAPSHOT
TABLE 183. PAREXEL: SERVICE SEGMENTS
TABLE 184. PAREXEL: PRODUCT PORTFOLIO
TABLE 185. PAREXEL: KEY STRATERGIES

List Of Figures

LIST OF FIGURES

FIGURE 01. PHARMACOVIGILANCE MARKET, 2024-2034

FIGURE 02. SEGMENTATION OF PHARMACOVIGILANCE MARKET, 2024-2034

FIGURE 03. TOP IMPACTING FACTORS IN PHARMACOVIGILANCE MARKET (2024 TO 2034)

FIGURE 04. TOP INVESTMENT POCKETS IN PHARMACOVIGILANCE MARKET (2025-2034)

FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 06. HIGH THREAT OF NEW ENTRANTS

FIGURE 07. MODERATE THREAT OF SUBSTITUTES

FIGURE 08. MODERATE INTENSITY OF RIVALRY

FIGURE 09. MODERATE BARGAINING POWER OF BUYERS

FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET: DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 11. PHARMACOVIGILANCE MARKET, BY TYPE, 2024 AND 2034(%)

FIGURE 12. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR SERVICES, BY COUNTRY 2024 AND 2034(%)

FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR SOFTWARE, BY COUNTRY 2024 AND 2034(%)

FIGURE 14. PHARMACOVIGILANCE MARKET, BY PROCESS FLOW, 2024 AND 2034(%)

FIGURE 15. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR PRE-MARKETING, BY COUNTRY 2024 AND 2034(%)

FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR POST-MARKETING, BY COUNTRY 2024 AND 2034(%)

FIGURE 17. PHARMACOVIGILANCE MARKET, BY DEPLOYMENT, 2024 AND 2034(%)

FIGURE 18. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR IN HOUSE, BY COUNTRY 2024 AND 2034(%)

FIGURE 19. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR CONTRACT OUTSOURCING, BY COUNTRY 2024 AND 2034(%)

FIGURE 20. PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA, 2024 AND 2034(%)

FIGURE 21. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR ONCOLOGY, BY COUNTRY 2024 AND 2034(%)

FIGURE 22. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE

MARKET FOR NEUROLOGY, BY COUNTRY 2024 AND 2034(%)

FIGURE 23. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR CARDIOLOGY, BY COUNTRY 2024 AND 2034(%)

FIGURE 24. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR RESPIRATORY SYSTEMS, BY COUNTRY 2024 AND 2034(%)

FIGURE 25. COMPARATIVE SHARE ANALYSIS OF PHARMACOVIGILANCE MARKET FOR OTHERS, BY COUNTRY 2024 AND 2034(%)

FIGURE 26. PHARMACOVIGILANCE MARKET BY REGION, 2024 AND 2034(%)

FIGURE 27. U.S. PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 28. CANADA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 29. MEXICO PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 30. GERMANY PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 31. FRANCE PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 32. UK PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 33. ITALY PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 34. SPAIN PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 35. REST OF EUROPE PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 36. JAPAN PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 37. CHINA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 38. INDIA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 39. AUSTRALIA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 40. SOUTH KOREA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 41. REST OF ASIA-PACIFIC PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 42. BRAZIL PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 43. SAUDI ARABIA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 44. SOUTH AFRICA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 45. REST OF LAMEA PHARMACOVIGILANCE MARKET, 2024-2034 (\$MILLION)

FIGURE 46. TOP WINNING STRATEGIES, BY YEAR (2023-2025)

FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT (2023-2025)

FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY (2023-2025)

FIGURE 49. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 50. COMPETITIVE DASHBOARD

FIGURE 51. COMPETITIVE HEATMAP: PHARMACOVIGILANCE MARKET

FIGURE 52. TOP PLAYER POSITIONING, 2024

FIGURE 53. ACCENTURE: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 54. ACCENTURE: RESEARCH & DEVELOPMENT EXPENDITURE, 2022-2024 (\$MILLION)

FIGURE 55. ACCENTURE: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 56. ACCENTURE: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 57. COGNIZANT: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 58. COGNIZANT: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 59. COGNIZANT: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 60. ORACLE CORPORATION: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 61. ORACLE CORPORATION: RESEARCH & DEVELOPMENT EXPENDITURE, 2022-2024 (\$MILLION)

FIGURE 62. ORACLE CORPORATION: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 63. ORACLE CORPORATION: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 64. LABCORP: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 65. LABCORP: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 66. WIPRO LIMITED: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 67. WIPRO LIMITED: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 68. WIPRO LIMITED: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 69. ICON PLC: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 70. ICON PLC: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 71. CAPGEMINI: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 72. CAPGEMINI: REVENUE SHARE BY REGION, 2024 (%)

FIGURE 73. CAPGEMINI: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 74. IQVIA: NET REVENUE, 2022-2024 (\$MILLION)

FIGURE 75. IQVIA: REVENUE SHARE BY SEGMENT, 2024 (%)

FIGURE 76. IQVIA: REVENUE SHARE BY REGION, 2022 (%)

I would like to order

Product name: Pharmacovigilance Market By Type (Services, Software), By Process Flow (Pre-marketing, Post-marketing), By Deployment (In House, Contract Outsourcing), By Therapeutic Area (Oncology, Neurology, Cardiology, Respiratory Systems, Others): Global Opportunity Analysis and Industry Forecast, 2025-2034

Product link: <https://marketpublishers.com/r/P9502064F9AAEN.html>

Price: US\$ 2,655.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P9502064F9AAEN.html>